Care cascade of tuberculosis infection treatment for people living with HIV in the era of antiretroviral therapy scale-up
© 2022. The Author(s)..
Testing and treatment of tuberculosis infection (TBI) are recommended for people living with HIV (PLWH). We aimed to evaluate the care cascade of TBI treatment among PLWH in the era of antiretroviral therapy (ART) scale-up. This retrospective study included adult PLWH undergoing interferon-gamma release assay (IGRA)-based TBI screening during 2019-2021. PLWH testing IGRA-positive were advised to receive directly-observed therapy for TBI after active TB disease was excluded. The care cascade was evaluated to identify barriers to TBI management. Among 7951 PLWH with a median age of 38 years and CD4 count of 616 cells/mm3, 420 (5.3%) tested positive and 38 (0.5%) indeterminate for IGRA. The TBI treatment initiation rate was 73.6% (309/420) and the completion rate was 91.9% (284/309). More than 80% of PLWH concurrently received short-course rifapentine-based regimens and integrase strand transfer inhibitor (InSTI)-containing ART. The main barrier to treatment initiation was physicians' concerns and patients' refusal (85.6%). The factors associated with treatment non-completion were older age, female, anti-HCV positivity, and higher plasma HIV RNA. Our observation of a high TBI completion rate among PLWH is mainly related to the introduction of short-course rifapentine-based regimens in the InSTI era, which can be the strategy to improve TBI treatment uptake.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Scientific reports - 12(2022), 1 vom: 27. Sept., Seite 16136 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Kuan-Yin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 29.09.2022 Date Revised 28.11.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-022-20394-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346833566 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346833566 | ||
| 003 | DE-627 | ||
| 005 | 20231226205326.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-022-20394-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM346833566 | ||
| 035 | |a (NLM)36167744 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Kuan-Yin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Care cascade of tuberculosis infection treatment for people living with HIV in the era of antiretroviral therapy scale-up |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.09.2022 | ||
| 500 | |a Date Revised 28.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Testing and treatment of tuberculosis infection (TBI) are recommended for people living with HIV (PLWH). We aimed to evaluate the care cascade of TBI treatment among PLWH in the era of antiretroviral therapy (ART) scale-up. This retrospective study included adult PLWH undergoing interferon-gamma release assay (IGRA)-based TBI screening during 2019-2021. PLWH testing IGRA-positive were advised to receive directly-observed therapy for TBI after active TB disease was excluded. The care cascade was evaluated to identify barriers to TBI management. Among 7951 PLWH with a median age of 38 years and CD4 count of 616 cells/mm3, 420 (5.3%) tested positive and 38 (0.5%) indeterminate for IGRA. The TBI treatment initiation rate was 73.6% (309/420) and the completion rate was 91.9% (284/309). More than 80% of PLWH concurrently received short-course rifapentine-based regimens and integrase strand transfer inhibitor (InSTI)-containing ART. The main barrier to treatment initiation was physicians' concerns and patients' refusal (85.6%). The factors associated with treatment non-completion were older age, female, anti-HCV positivity, and higher plasma HIV RNA. Our observation of a high TBI completion rate among PLWH is mainly related to the introduction of short-course rifapentine-based regimens in the InSTI era, which can be the strategy to improve TBI treatment uptake | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a Integrases |2 NLM | |
| 650 | 7 | |a EC 2.7.7.- |2 NLM | |
| 700 | 1 | |a Yang, Chia-Jui |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Hsin-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Yuan-Ti |e verfasserin |4 aut | |
| 700 | 1 | |a Liou, Bo-Huang |e verfasserin |4 aut | |
| 700 | 1 | |a Hii, Ing-Moi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tun-Chieh |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Sung-Hsi |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Chun-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Chin-Shiang |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chi-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chun-Eng |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Hsi-Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Chien-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Po-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Chien-Ching |e verfasserin |4 aut | |
| 700 | 0 | |a Taiwan HIV Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yu-Shan |e investigator |4 oth | |
| 700 | 1 | |a Liu, Wang-Da |e investigator |4 oth | |
| 700 | 1 | |a Chen, Guan-Jhou |e investigator |4 oth | |
| 700 | 1 | |a Liu, Wen-Chun |e investigator |4 oth | |
| 700 | 1 | |a Su, Yi-Ching |e investigator |4 oth | |
| 700 | 1 | |a Wu, Pei-Ying |e investigator |4 oth | |
| 700 | 1 | |a Chen, Ling-Ya |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Jun-Yu |e investigator |4 oth | |
| 700 | 1 | |a Tsai, Mao-Song |e investigator |4 oth | |
| 700 | 1 | |a Lin, Chia-Chun |e investigator |4 oth | |
| 700 | 1 | |a Lee, Yu-Lin |e investigator |4 oth | |
| 700 | 1 | |a Chen, Yen-Hsu |e investigator |4 oth | |
| 700 | 1 | |a Huang, Yi-Chia |e investigator |4 oth | |
| 700 | 1 | |a Ko, Wen-Chien |e investigator |4 oth | |
| 700 | 1 | |a Cheng, Shu-Hsing |e investigator |4 oth | |
| 700 | 1 | |a Chang, Sui-Yuan |e investigator |4 oth | |
| 700 | 1 | |a Wang, Ning-Chi |e investigator |4 oth | |
| 700 | 1 | |a Lin, Te-Yu |e investigator |4 oth | |
| 700 | 1 | |a Lee, Yi-Chieh |e investigator |4 oth | |
| 700 | 1 | |a Lin, Shih-Ping |e investigator |4 oth | |
| 700 | 1 | |a Hsieh, Chia-Yin |e investigator |4 oth | |
| 700 | 1 | |a Wang, Hsiu-Wen |e investigator |4 oth | |
| 700 | 1 | |a Ho, Mao-Wang |e investigator |4 oth | |
| 700 | 1 | |a Hung, Tung-Che |e investigator |4 oth | |
| 700 | 1 | |a Tsai, Hung-Chin |e investigator |4 oth | |
| 700 | 1 | |a Lin, Hsi-Hsun |e investigator |4 oth | |
| 700 | 1 | |a Lee, Chen-Hsiang |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 27. Sept., Seite 16136 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:27 |g month:09 |g pages:16136 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-022-20394-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 27 |c 09 |h 16136 | ||